Drastically Reduce Oral Cancer Recurrence
Oral cancer recurrence is a devastating reality that affects up to 40% of patients who undergo conventional surgical treatment. However, breakthrough technology is now changing these statistics dramatically. With advanced fluorescence visualization and DNA ploidy testing, we can reduce oral cancer recurrence rates from 40% to as low as 6.5%, representing a game-changing advancement in oral cancer care.
The Current Crisis: High Recurrence Rates
Traditional Surgery Limitations
Limited visualization:
Under white light examination, it’s difficult to identify the exact boundaries of malignant tissue
Inadequate margins:
Late-stage oral cancer treatment is 5-10 times more expensive than early detection, straining healthcare budgets
Incomplete removal:
Microscopic cancer cells may remain at surgical sites, leading to recurrence
High recurrence rates:
Up to 40% of patients experience cancer recurrence after conventional surgery
The Cost of recurrence
Reduced Survival rates:
Recurrent cancer is typically more aggressive and harder to treat
increase treatment cost:
Second surgeries, chemotherapy, and radiation therapy multiply expenses
Diminished quality of life:
Repeated treatments cause physical and emotional trauma
Economic burden:
Treatment costs can exceed annual family income by 5-10 times
Revolutionary Solution: Fluorescence-Guided Surgery
VELscope Vx Technology
The VELscope Vx represents a paradigm shift in oral cancer surgery, utilizing tissue fluorescence visualization (TFV) to identify malignant tissue invisible to the naked eye.
How it works:
Blue light excitation: The device emits a specific wavelength of blue light
Cancer detection: Abnormal tissue shows loss of fluorescence and appears dark
Tissue response: Normal tissue fluoresces and appears as an apple-green glow
Real-time guidance: Surgeons can visualize the exact extent of cancerous tissue during surgery
Proven Results: Dramatic Recurrence Reduction
Clinical studies demonstrate the remarkable effectiveness of fluorescence-guided surgery:
92 patients with squamous cell carcinoma: 3-year local recurrence rate reduced from 40.6% to 6.5%
62 patients with high-grade lesions: Recurrence rate decreased from 39.3% to 8.1%
Overall reduction: Over 90% decrease in recurrence rates when VELscope guidance is used
Advanced Detection: DNA Ploidy Testing
DNA ploidy testing measures cellular aneuploidy, the fundamental biomarker of cancer, providing quantitative data about cell behavior at the molecular level.
98% sensitivity and 100% specificity: Unmatched accuracy in detecting abnormal cells
Objective results: Eliminates subjective interpretation and observer bias
Early detection: Identifies cancer up to 2 years before conventional methods
Quantitative data: Provides precise measurements of DNA content in each cell
Pre-Treatment Planning
DNA ploidy testing before surgery establishes crucial baseline data:
Aneuploidy mapping: Identifies the extent of abnormal cell distribution
Treatment optimization: Guides surgical planning and margin determination
Prognosis assessment: Predicts treatment response and recurrence risk
Monitoring foundation: Creates baseline for post-treatment surveillance
Benefits of Advanced Technology
Immediate Clinical Benefits
Precise surgical margins: Fluorescence visualization eliminates guesswork
Complete tumor removal: Ensures no malignant tissue remains
Reduced operative time: Real-time guidance streamlines procedures
Improved outcomes: Dramatically lower recurrence rates
Long-Term Patient Benefits
Enhanced survival rates: Early detection and complete removal improve prognosis
Better quality of life: Reduced need for repeat surgeries and treatments
Lower treatment costs: Prevention of recurrence eliminates expensive second treatments
Increased confidence: Patients have greater assurance of successful treatment
Healthcare System Benefits
Cost reduction: Preventing recurrence saves substantial healthcare resources
Improved efficiency: Precise surgery reduces complications and readmissions
Enhanced reputation: Superior outcomes attract more patients
Increased confidence: Patients have greater assurance of successful treatment
Post-Treatment Surveillance Non-Invasive Monitoring
VELscope Vx Technology
Advanced technology enables comprehensive post-treatment surveillance:
Regular VELscope Examinations:
Visual monitoring: Detects changes in fluorescence patterns
Early warning system: Identifies suspicious areas before clinical symptoms
Patient comfort: Non-invasive procedure with high patient acceptance
Recommended Surveillance Schedule
First 3 months: Monthly examinations
3-12 months: Quarterly assessments
1-3 years: Bi-annual monitoring
Beyond 3 years: Annual surveillance
What experts have to say:
“We see recurrence rate decrease significantly in both, invasive cancers and cases of severe dysplasia, when surgical margins are determined using Tissue Fluores-cence Visualization.”
Dr. Calum MacAulay PhD Clinical Associate Professor, UBC
Head of Integrative Oncology Distinguished Scientist Serves as Head, Cancer Imaging Department, B.C. Cancer Research Centre, BCAA
“With FV technology we found that the extension of this disease is not uniform around the cancerous area, so a 10-mm margin around the tumor site may not always work. With the use of FV technology, we hope to accurately remove all cancerous tissue.”
Prof. Dr. Catherine F. Poh, DDS, PhD, FRCD (C), Clinician Scientist, Oral Pathologist and Consulting Dentist, BC, Canada.
“VELscope allows us to add new dimension to detect abnormalities which may be histologic or perhaps only genetic and use those in real time way to evaluate surgical margins”
Prof. J. Scott Durham, BSc MD FRCSC Head, VGH Otolaryngology – Head and Neck Surgery
Oral cancer recurrence is no longer inevitable. With advanced fluorescence visualization and DNA ploidy testing, we can reduce recurrence rates by over 90%, transforming outcomes for oral cancer patients.
The choice is clear: continue with conventional methods that leave too many patients vulnerable to recurrence, or embrace technology that dramatically improves survival rates and quality of life.
The power to drastically reduce oral cancer recurrence is available today. The question is not whether this technology works—the evidence is overwhelming.
The question is whether we will act decisively to implement it and save lives.
Don’t let oral cancer return. Demand the best technology for the best outcomes.